Evidence map›Paper›PMID 41784265›Full record

ArticleNucleic acids research2026

Control of retrotransposon-driven activation of the interferon response by the double-stranded RNA binding protein DGCR8.

Ana Gázquez-Gutiérrez, Priscilla Chin, Guillermo Peris, Katrina Gordon, Pilar G Marchante, Jeroen Witteveldt, Pablo Tristán-Ramos, Jerome O Rouvière, Lisanne I Knol, Alasdair Ivens and 6 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ana Gázquez-GutiérrezDepartment of Biochemistry and Molecular Biology II, Faculty of Pharmacy, University of Granada, Granada 18071, Spain.
Priscilla ChinInstitute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3FL, UK.
Guillermo PerisGENYO. Centre for Genomics and Oncological Research, Pfizer University of Granada, Andalusian Regional Government. PTS Granada, Av. de la Ilustración, 114, 18016, Granada, Spain.
Katrina GordonInstitute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3FL, UK.
Pilar G MarchanteDepartment of Biochemistry and Molecular Biology II, Faculty of Pharmacy, University of Granada, Granada 18071, Spain.
Jeroen WitteveldtInstitute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3FL, UK.
Pablo Tristán-RamosDepartment of Biochemistry and Molecular Biology II, Faculty of Pharmacy, University of Granada, Granada 18071, Spain.
Jerome O RouvièreDepartment of Molecular Biology and Genetics, Universitetsbyen 81, Aarhus University, Aarhus DK8000, Denmark.
Lisanne I KnolInstitute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3FL, UK.
Alasdair IvensInstitute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3FL, UK.
Lourdes López-OnievaGENYO. Centre for Genomics and Oncological Research, Pfizer University of Granada, Andalusian Regional Government. PTS Granada, Av. de la Ilustración, 114, 18016, Granada, Spain.
Antonio M EstévezInstitute of Parasitology and Biomedicine 'López-Neyra', Spanish National Research Council, Granada 18016, Spain.ORCID 0000-0002-8272-5405
William GarlandDepartment of Molecular Biology and Genetics, Universitetsbyen 81, Aarhus University, Aarhus DK8000, Denmark.
Torben H JensenDepartment of Molecular Biology and Genetics, Universitetsbyen 81, Aarhus University, Aarhus DK8000, Denmark.ORCID 0000-0001-5127-1239
Sara R HerasDepartment of Biochemistry and Molecular Biology II, Faculty of Pharmacy, University of Granada, Granada 18071, Spain.
Sara MaciasInstitute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3FL, UK.ORCID 0000-0002-0643-3494

Funding

Royal Society RGS\R1\191368Wellcome Trust 221737/Z/20/Z
6 · The paper itself

Abstract

The type I interferon (IFN) response is the main innate immune pathway against viruses in mammals. This pathway must be tightly regulated to prevent viral spread while avoiding excessive immune responses. Here, we show that inactivation of the double-stranded RNA (dsRNA)-binding protein DGCR8 unleashes the IFN response in human cells. We demonstrate that DGCR8 restricts the accumulation of endogenous dsRNA originating from protein-coding mRNAs that harbour transposable elements (TEs), primarily LINE and SINE elements. We propose that DGCR8 binding to TE-rich mRNAs is essential to resolve dsRNA structures, and in its absence, accumulated dsRNA signals through the MDA5-MAVS pathway trigger the IFN response. This mechanism is relevant to conditions where DGCR8 expression levels are altered, including the 22q11.2 deletion syndrome (22qDS). Supporting this, we show that 22qDS-derived cells exhibit an exacerbated type I IFN response, which inversely correlated with DGCR8 levels. All these together demonstrate the importance of suppressing endogenous TE-dsRNA accumulation to prevent unwanted immune activation and associated disease pathogenesis.

Indexed as

Interferon Type IRetroelementsRNA-Binding ProteinsRNA, Double-StrandedAdaptor Proteins, Signal TransducingCell LineHumansImmunity, InnateInterferon-Induced Helicase, IFIH1RNA, MessengerSignal TransductionAdaptor Proteins, Signal TransducingDGCR8 protein, humanIFIH1 protein, humanInterferon-Induced Helicase, IFIH1Interferon Type IMAVS protein, humanRetroelementsRNA-Binding ProteinsRNA, Double-StrandedRNA, Messenger

Identifiers

PMID41784265
PMCPMC12961426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.